Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Melcher

Showing results (21-30 of 134) with videos related to

Pageof 14
Sort By:
Cancer Immunology, Immunotherapy : CII|December 7, 2007
Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapyAlison Merrick, Rosa Maria Diaz, Dearbhaile O'Donnell, et al.
BMC Immunology|March 23, 2010
Differential effects of Paclitaxel on dendritic cell functionJustin John, Mohammed Ismail, Catherine Riley, et al.
Viruses|December 4, 2015
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Samantha Turnbull, Emma J West, Karen J Scott, et al.
Oncolytic Virotherapy|August 12, 2016
Applications of coxsackievirus A21 in oncologyStephen Bradley, Adam D Jakes, Kevin Harrington, et al.
Clinical Medicine. Oncology|September 6, 2011
Oncolytic viruses: do they have a role in anti-cancer therapy?Robin J Prestwich, Fiona Errington, Kevin J Harrington, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 21, 2010
VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signalingPhonphimon Wongthida, Rosa M Diaz, Feorillo Galivo, et al.
International Journal of Cancer|May 31, 2007
CD40-mediated death and cytokine secretion in colorectal cancer: a potential target for inflammatory tumour cell killingNikolaos T Georgopoulos, Alison Merrick, Nigel Scott, et al.
NPJ Breast Cancer|July 24, 2025
The untapped potential of radiation and immunotherapy for hormone receptor-positive breast cancerMatthew Fenton, Miki Yoneyama, Erik Wennerberg, et al.
Current Cancer Drug Targets|March 6, 2010
The biology of the sodium iodide symporter and its potential for targeted gene deliveryMohan Hingorani, Christine Spitzweg, Georges Vassaux, et al.
Expert Opinion on Biological Therapy|December 3, 2015
Talimogene laherparepvec in the treatment of melanomaElizabeth S Appleton, Samantha Turnbull, Christy Ralph, et al.
Pageof 14

Showing results (21-30 of 134) with videos related to

Sort By:
Pageof 14
Cancer Immunology, Immunotherapy : CII|December 7, 2007
Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapyAlison Merrick, Rosa Maria Diaz, Dearbhaile O'Donnell, et al.
BMC Immunology|March 23, 2010
Differential effects of Paclitaxel on dendritic cell functionJustin John, Mohammed Ismail, Catherine Riley, et al.
Viruses|December 4, 2015
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Samantha Turnbull, Emma J West, Karen J Scott, et al.
Oncolytic Virotherapy|August 12, 2016
Applications of coxsackievirus A21 in oncologyStephen Bradley, Adam D Jakes, Kevin Harrington, et al.
Clinical Medicine. Oncology|September 6, 2011
Oncolytic viruses: do they have a role in anti-cancer therapy?Robin J Prestwich, Fiona Errington, Kevin J Harrington, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 21, 2010
VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signalingPhonphimon Wongthida, Rosa M Diaz, Feorillo Galivo, et al.
International Journal of Cancer|May 31, 2007
CD40-mediated death and cytokine secretion in colorectal cancer: a potential target for inflammatory tumour cell killingNikolaos T Georgopoulos, Alison Merrick, Nigel Scott, et al.
NPJ Breast Cancer|July 24, 2025
The untapped potential of radiation and immunotherapy for hormone receptor-positive breast cancerMatthew Fenton, Miki Yoneyama, Erik Wennerberg, et al.
Current Cancer Drug Targets|March 6, 2010
The biology of the sodium iodide symporter and its potential for targeted gene deliveryMohan Hingorani, Christine Spitzweg, Georges Vassaux, et al.
Expert Opinion on Biological Therapy|December 3, 2015
Talimogene laherparepvec in the treatment of melanomaElizabeth S Appleton, Samantha Turnbull, Christy Ralph, et al.
Pageof 14